Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal
| Autor: | N F Ngom Gueye, P.S. Sow, Pierre-Marie Girard, D Thiam, Eric Delaporte, B Ndiaye, Roland Landman, M Poupard |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Cyclopropanes Male Sleep Wake Disorders medicine.medical_specialty Efavirenz Anti-HIV Agents Cross-sectional study HIV Infections chemistry.chemical_compound Quality of life Antiretroviral Therapy Highly Active Internal medicine medicine Humans Pharmacology (medical) Sex Distribution Adverse effect Psychiatry Depression (differential diagnoses) Reverse-transcriptase inhibitor Depression business.industry Health Policy efavirenz HIV Protease Inhibitors Center for Epidemiologic Studies Depression Scale HIV infection Senegal Benzoxazines Regimen Cross-Sectional Studies Infectious Diseases depression score quality of life chemistry Alkynes Quality of Life sub Saharan Africa Female business medicine.drug |
| Zdroj: | HIV Medicine. 8:92-95 |
| ISSN: | 1468-1293 1464-2662 |
| DOI: | 10.1111/j.1468-1293.2007.00435.x |
| Popis: | Background Efavirenz has been associated with neuropsychiatric disorders, but little is known about depression and quality of life in sub-Saharan Africa, where nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are still the first-line treatment recommended by the World Heath Organization (WHO) and are widely prescribed. Methods In a cross-sectional study, we evaluated quality of life and depression among Senegalese patients receiving efavirenz- or protease inhibitor (PI)-based regimens. Two hundred consecutive patients who had been taking highly active antiretroviral therapy (HAART) for more than 6 months were asked to complete a questionnaire. Results According to the Center for Epidemiologic Studies Depression Scale (CES-D), 18% had depression (19% for patients on a PI-based regimen and 17% for patients on efavirenz-based treatment). Fifty-nine per cent of the patients reported no health problems in the past 4 weeks. A quarter of patients had sleep disorders. Moderate or slight adverse events were reported by 28.5% of patients. Conclusions Quality of life and depression scores remained good in both study groups. However, quality of life and depression should be monitored in follow-up of HIV-infected patients in sub-Saharan Africa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|